Literature DB >> 27150369

Chemistry and Bioactivities of Aristeromycins: An Overview.

Ravindra K Rawal1, Jitender Bariwal, Virender Singh.   

Abstract

The majority of carbocyclic nucleosides are of synthetic origin; nature has provided two of the most interesting compounds, aristeromycin and neplanocin A. Aristeromycin and its modified derivatives are an important group of carbocyclic nucleosides that exhibits a wide range of pharmacological properties such as antiviral, anticancer and antitoxoplasma activities. Especially, aristeromycins are widely used as antiviral agents against human immunodeficiency virus, hepatitis B virus, herpes simplex virus, varicella-zoster virus, influenza virus and hepatitis C virus. These potential antiviral and other biological applications of aristeromycin have motivated new effort in search for novel modified aristeromycin derivatives with improved biological activities. Owing to the importance of aristeromycin and its derivatives, the aim of this review is to highlight the aspects reported on the chemistry and bioactivities of aristeromycins.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27150369     DOI: 10.2174/1568026616666160506145300

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin.

Authors:  Ramakrishnamraju Samunuri; Masaaki Toyama; Renuka Sivasankar Pallaka; Seshubabu Neeladri; Ashok Kumar Jha; Masanori Baba; Chandralata Bal
Journal:  RSC Med Chem       Date:  2020-05-15

2.  Antiviral nucleoside analogs.

Authors:  Vladimir E Kataev; Bulat F Garifullin
Journal:  Chem Heterocycl Compd (N Y)       Date:  2021-05-14       Impact factor: 1.277

Review 3.  The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold.

Authors:  Katherine L Seley-Radtke; Mary K Yates
Journal:  Antiviral Res       Date:  2018-04-10       Impact factor: 10.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.